A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the company's book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.

Medpace Holdings faces a securities class action lawsuit alleging the company made false and misleading statements about its backlog cancellation rates. The company guided investors toward a 1.15 book-to-bill ratio but reported only 1.04 in Q4 2025, causing the stock to plummet 15.9% on February 10, 2026. Shareholders who purchased shares between April 22, 2025 and February 9, 2026 are encouraged to register, with a June 8, 2026 deadline to seek lead plaintiff status.

Rosen Law Firm has filed securities class action lawsuits against Medpace Holdings, Vital Farms, and monday.com Ltd. on behalf of investors who purchased shares during specified periods. The lawsuits allege that defendants made false or misleading statements regarding business metrics and financial performance, resulting in investor damages.

Robbins LLP has filed a class action lawsuit against Medpace Holdings Inc. (MEDP) for allegedly misleading investors about its expected book-to-bill ratio. The company guided investors toward a 1.15 ratio but announced a 1.04 ratio on February 9, 2026, causing the stock to plummet 15.9% in a single day. Shareholders who purchased securities between April 22, 2025 and February 9, 2026 may be eligible to participate in the class action.

Robbins Geller has announced a class action lawsuit against Medpace Holdings Inc. for alleged securities fraud. The lawsuit claims Medpace made false statements about its book-to-bill ratio projections and failed to disclose the impact of cancellations on its business. When Medpace reported a fourth quarter 2025 book-to-bill ratio of 1.04, significantly below its 1.15 guidance, the stock fell nearly 16%. Investors with substantial losses can seek appointment as lead plaintiff by June 8, 2026.

A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the company's book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.

Robbins LLP has filed a class action lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP) alleging the company misled investors regarding its expected book-to-bill ratio. Medpace guided investors toward a 1.15 ratio but announced a 1.04 ratio on February 9, 2026, causing the stock to plummet 15.9% from $530.35 to $446.05 per share. Shareholders who purchased securities between April 22, 2025 and February 9, 2026 may be eligible to participate in the class action.

A class action lawsuit has been filed against Medpace Holdings Inc. for allegedly making false statements about its book-to-bill ratio projections for Q4 2025. The company guided investors toward a 1.15 ratio but delivered only 1.04, causing the stock to fall nearly 16% on February 9, 2026. Investors who purchased shares between April 22, 2025 and February 9, 2026 can seek lead plaintiff status by June 8, 2026.

Faruqi & Faruqi, LLP is investigating potential securities fraud claims against Medpace Holdings, Inc. The lawsuit alleges that defendants made false and misleading statements about the company's backlog cancellation rates while providing overly positive growth expectations. Medpace's stock price fell 15.9% on February 10, 2026, after announcing a book-to-bill ratio of 1.04, significantly below the guided 1.15. The deadline to seek lead plaintiff status is June 8, 2026.

Law firm Levi & Korsinsky has filed a class action lawsuit against Medpace Holdings, Inc. on behalf of shareholders who purchased stock between April 22, 2025 and February 9, 2026. The complaint alleges that Medpace made false and misleading statements about its backlog cancellation rates while concealing material adverse facts. The company's stock price fell over 15.9% on February 10, 2026, after announcing a fourth quarter 2025 book-to-bill ratio of 1.04, significantly below the previously guided 1.15. The lead plaintiff deadline is set for June 8, 2026.

A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information. Investors who purchased Medpace securities during this period are encouraged to join the case, with a lead plaintiff deadline of June 5, 2026.

Large stock price swings like Medpace's recent 55% jump are typically driven by identifiable factors such as short squeezes or concentrated trading rather than pure market randomness. Investors should distinguish between moves based on corporate developments versus those fueled by momentum or retail trading, as each carries different risks and implications for long-term value.